Cargando…
BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1
Ovarian cancer is responsible for the highest mortality among all gynecologic malignancies, and novel therapies are urgently needed to improve patient outcome. Here we performed an integrative genomic analysis and identified the bromodomain and extraterminal domain (BET) protein BRD4 as a potential...
Autores principales: | Zhang, Zhenfeng, Ma, Pengfei, Jing, Ying, Yan, Ying, Cai, Mei-Chun, Zhang, Meiying, Zhang, Shengzhe, Peng, Huixin, Ji, Zhi-Liang, Di, Wen, Gu, Zhenyu, Gao, Wei-Qiang, Zhuang, Guanglei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729770/ https://www.ncbi.nlm.nih.gov/pubmed/26877780 http://dx.doi.org/10.7150/thno.13178 |
Ejemplares similares
-
Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer
por: Zhang, Shengzhe, et al.
Publicado: (2015) -
Concomitant BET and MAPK blockade for effective treatment of ovarian cancer
por: Jing, Ying, et al.
Publicado: (2015) -
PAX8 regulon in human ovarian cancer links lineage dependency with epigenetic vulnerability to HDAC inhibitors
por: Shi, Kaixuan, et al.
Publicado: (2019) -
Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors
por: Zhang, Shengzhe, et al.
Publicado: (2018) -
Selective inhibition of BET bromodomains
por: Filippakopoulos, Panagis, et al.
Publicado: (2010)